Karyopharm Announces Management Change

4/4/17

NEWTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin Renz, Executive Vice President, Chief Financial Officer and Treasurer, has stepped down in order to pursue other opportunities, effective today. Mr. Renz will continue to serve the Company in an advisory capacity in order to ensure a smooth transition.

“The Board and I wish to express our gratitude to Justin for his outstanding contributions and service to Karyopharm’s leadership team,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. “He has played an important role in building Karyopharm into a leading oncology company and has helped establish an internal organization that is well-equipped to advance the Company’s strategy moving forward. We wish him all the best in his future endeavors.”

Karyopharm has begun a search process for the selection and appointment of a new Chief Financial Officer. In the interim, Michael Todisco, who has served as the Company’s Vice President, Finance, will lead its internal finance function.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,900 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.